Blueprint Medicines Corp (BPMC)
94.15
-2.47
(-2.56%)
USD |
NASDAQ |
Nov 22, 16:00
94.20
+0.05
(+0.05%)
After-Hours: 20:00
Blueprint Medicines Total Liabilities (Quarterly): 886.50M for Sept. 30, 2024
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 886.50M |
| June 30, 2024 | 883.32M |
| March 31, 2024 | 727.79M |
| December 31, 2023 | 918.64M |
| September 30, 2023 | 902.69M |
| June 30, 2023 | 795.32M |
| March 31, 2023 | 806.07M |
| December 31, 2022 | 835.22M |
| September 30, 2022 | 818.08M |
| June 30, 2022 | 444.70M |
| March 31, 2022 | 261.64M |
| December 31, 2021 | 281.49M |
| September 30, 2021 | 230.24M |
| June 30, 2021 | 239.99M |
| March 31, 2021 | 225.37M |
| December 31, 2020 | 248.30M |
| September 30, 2020 | 238.18M |
| June 30, 2020 | 236.09M |
| March 31, 2020 | 230.69M |
| December 31, 2019 | 243.34M |
| Date | Value |
|---|---|
| September 30, 2019 | 221.58M |
| June 30, 2019 | 214.35M |
| March 31, 2019 | 200.45M |
| December 31, 2018 | 121.12M |
| September 30, 2018 | 116.81M |
| June 30, 2018 | 112.18M |
| March 31, 2018 | 93.60M |
| December 31, 2017 | 91.77M |
| September 30, 2017 | 78.88M |
| June 30, 2017 | 70.63M |
| March 31, 2017 | 64.43M |
| December 31, 2016 | 69.72M |
| September 30, 2016 | 70.14M |
| June 30, 2016 | 73.96M |
| March 31, 2016 | 76.35M |
| December 31, 2015 | 34.92M |
| September 30, 2015 | 37.15M |
| June 30, 2015 | 34.62M |
| March 31, 2015 | 31.19M |
| December 31, 2014 | 14.50M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
225.37M
Minimum
Mar 2021
918.64M
Maximum
Dec 2023
522.68M
Average
363.09M
Median
Total Liabilities (Quarterly) Benchmarks
| Biomarin Pharmaceutical Inc | 1.438B |
| Regeneron Pharmaceuticals Inc | 8.116B |
| NovaBay Pharmaceuticals Inc | 2.805M |
| Palatin Technologies Inc | 11.10M |
| iBio Inc | 6.763M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 1.200B |
| Shareholders Equity (Quarterly) | 313.15M |
| Debt to Equity Ratio | 1.234 |
| Current Ratio | 3.318 |
| Net Debt Paydown Yield | -0.84% |